HC Wainwright Forecasts Zura Bio’s Q1 Earnings (NASDAQ:ZURA)

Zura Bio Limited (NASDAQ:ZURA) – Research analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Zura Bio in a note issued to investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.21) per share for the quarter, down from their prior estimate of ($0.20). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Zura Bio’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.85) EPS.

A number of other brokerages have also recently issued reports on ZURA. Chardan Capital cut their target price on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Guggenheim reissued a “buy” rating and set a $15.00 price objective on shares of Zura Bio in a report on Wednesday, March 26th. Oppenheimer restated an “outperform” rating and issued a $19.00 target price (down previously from $20.00) on shares of Zura Bio in a research note on Wednesday, March 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $14.67.

Zura Bio Stock Up 11.7 %

Shares of ZURA opened at $1.15 on Monday. The company has a 50-day moving average price of $1.39 and a two-hundred day moving average price of $2.61. The stock has a market cap of $78.63 million, a price-to-earnings ratio of -2.17 and a beta of 0.08. Zura Bio has a 12 month low of $0.97 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter.

Institutional Trading of Zura Bio

Several large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its position in Zura Bio by 51.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after buying an additional 98,972 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Zura Bio during the third quarter worth approximately $71,000. MetLife Investment Management LLC acquired a new position in shares of Zura Bio during the third quarter worth approximately $111,000. State Street Corp grew its stake in shares of Zura Bio by 47.5% during the third quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after purchasing an additional 127,300 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock valued at $260,000 after purchasing an additional 56,757 shares in the last quarter. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.